GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Yidu Tech Inc (HKSE:02158) » Definitions » Forward PE Ratio

Yidu Tech (HKSE:02158) Forward PE Ratio : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Yidu Tech Forward PE Ratio?

Yidu Tech's Forward PE Ratio for today is 0.00.

Yidu Tech's PE Ratio without NRI for today is 0.00.

Yidu Tech's PE Ratio for today is 0.00.


Yidu Tech Forward PE Ratio Historical Data

The historical data trend for Yidu Tech's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yidu Tech Forward PE Ratio Chart

Yidu Tech Annual Data
Trend
Forward PE Ratio

Yidu Tech Semi-Annual Data
Forward PE Ratio

Competitive Comparison of Yidu Tech's Forward PE Ratio

For the Health Information Services subindustry, Yidu Tech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yidu Tech's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Yidu Tech's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Yidu Tech's Forward PE Ratio falls into.



Yidu Tech Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Yidu Tech  (HKSE:02158) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Yidu Tech Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Yidu Tech's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Yidu Tech (HKSE:02158) Business Description

Traded in Other Exchanges
Address
No.9 Building of Huayuan North Road, 8th Floor Health Work, Haidian District, Beijing, CHN
Yidu Tech offers healthcare Big Data. It is an AI cloud-based firm providing solutions and tools to aid in more informed decisions to drive better efficiency in clients' strategies. Its clients are hospitals, pharmaceutical, biotech and medical device firms, research institutions, insurance companies, patients, and regulators. It three business segments are: Big Data platform and solutions, which partners with hospitals and policymakers to drive better efficiency; life sciences solutions, which enables better probability of clinical trial success with less drug development time and cost; and health management solutions, which helps with patient management. The Big Data platform accounted for 33% of revenue, life science solutions 30%, and health management solutions 27%, in fiscal 2022.
Executives
Gong Yingying 2202 Interest of your spouse
Xu Jiming 2101 Beneficial owner
Brunei Investment Agency 2101 Beneficial owner
Gic Private Limited 2102 Investment manager
Sweet Panda Limited 2101 Beneficial owner

Yidu Tech (HKSE:02158) Headlines

No Headlines